Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss

October 31, 2022
For the first time in more than 14 years, the Japanese health ministry is requiring a partial change of approval under its pharmaceutical reexamination system. Eisai’s Aricept (donepezil) now braces for such modification process, which also entails a label revision,...read more